Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807675 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
A Phase 1 study of Parkinson's Disease, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 11
- Study locations
NCT02807675: Completed Phase 1 study of Parkinson's Disease, sponsored by Acorda Therapeutics.
NCT02807675 is a Phase 1 study of Parkinson's Disease that has completed, run by Acorda Therapeutics. The registered enrollment target is 36 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (94% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02807675, a Phase 1 study of Parkinson's Disease, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is a double-blind, randomized, placebo-controlled, 2-way crossover study to evaluate the safety of CVT-301 levodopa (l-dopa) when co- administered with the first daily dose of oral levodopa/carbidopa for early morning OFF symptoms in patients with Parkinson's disease (PD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CVT-301, LIP
Study Locations (11)
Florida
- Site #9002 - Boca Raton
- Site #9017 - Hallandale
- Site #9008 - St. Petersburg
- Site #9018 - Sunrise
- Site #9004 - Tampa
Michigan
- Site #9003 - Farmington Hills
- Site #9005 - West Bloomfield
California
- Site #9015 - Fountain Valley
Georgia
- Site #9016 - Atlanta
Illinois
- Site #9009 - Chicago
Tennessee
- Site #9007 - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
What the finished NCT02807675 record still lists
NCT02807675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02807675 lists 11 locations in 6 states (Florida, Michigan, California).
Frequently Asked Questions
What is clinical trial NCT02807675 about?
NCT02807675 is a clinical study titled "A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)". This study is a double-blind, randomized, placebo-controlled, 2-way crossover study to evaluate the safety of CVT-301 levodopa (l-dopa) when co- administered with the first daily dose of oral levodopa/carbidopa for early morning OFF symptoms in patients with Parkinson's disease (PD).
What is the current status of trial NCT02807675?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-06. Estimated completion is 2016-11.
What conditions does trial NCT02807675 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT02807675?
The interventions under investigation include: Placebo (OTHER), CVT-301, LIP (DRUG).
Who is sponsoring clinical trial NCT02807675?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02807675 being conducted?
This trial has 11 study locations across California, Florida, Georgia, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02807675's enrollment target sits among peer trials
36 97th of 158 higher than 61 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia